Diabetes

Medication adherence is a complex topic that involves many barriers and obstacles; however, as Elizabeth A. Walker, PhD, RN, CDE, Director of the Prevention and Control Core, Einstein Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York, told her audience at this year's ADA 72nd Scientific Sessions, we must do something.

As a new era of personalized medicine continues to provide clues between genetic makeups and predispositions to certain disease states, researchers and providers are able to come up with more targeted therapies for patient populations.

Felicia Hill-Briggs, PhD, states that adherence and quality of life outcomes are equally important as comparative effectiveness research in clinical trials.

Medication adherence represents a major barrier to optimal therapeutic outcomes for a number of chronic conditions, and diabetes is no different. Often times, diabetes patients with poor glycemic control and multiple comorbidities have complex medication regimens, which often times complicate and exacerbate this problem.

In this video, Robert Gabbay, MD, PhD, talks about the overall cost implications to diabetes management through behavioral change.

To date, there has been no real-world comparative data published on the initiation of injectable therapy with insulin glargine disposable pen (GLA-P) of glucagons-like peptide-1 agonist liraglutide (LIRA) among type 2 diabetes patients. On day 1 of the American Diabetes Association's 72nd Scientific Sessions in Philadelphia, PA, an abstract was released by Levin et al which provided data from this exact comparative analysis.

Diabetes is a chronic condition that has been shown to be directly related to obesity and heart-related conditions. The strain that diabetes costs put on the healthcare system are well documented. At this year's 72nd Scientific Sessions, the American Diabetes Association featured several studies that aim to help rein in diabetes costs. Here are two studies that were highlighted.

Andrew J. M. Boulton, MD, describes the impact of non-invasive glucose monitoring devices on adherence and hospital admission rates.

The 72nd Scientific Sessions of the American Diabetes Association (ADA) will take place from June 8-12 at the Pennsylvania Convention Center in Philadelphia, PA.

The Diabetes Complications Severity Index without laboratory test results is a good measure of diabetes severity, given its ability to explain costs.

Cell phone“based text messaging may be used to feasibly support chronic disease management and engagement in diabetes self-care behaviors for some patients.

Nurses can improve lipid control in people with diabetes in a primarily indigent population through telephone care using moderately complex algorithms. Telephone-based outreach may decrease resource utilization.

Healthcare organizations may reduce weight-related health risks and disparities in care among overweight/obese patients through promoting cancer screening exams, healthier diets, and physical activity.

This paper explores hypertension control among patients with diabetes in a variety of ambulatory care settings. We also consider the role of sociodemographic factors.